We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04838041
Recruitment Status : Recruiting
First Posted : April 8, 2021
Last Update Posted : May 5, 2022
Sponsor:
Collaborator:
H. Jean Khoury Cure CML Consortium
Information provided by (Responsible Party):
Ehab L Atallah, Medical College of Wisconsin

Brief Summary:
This is a single-arm phase II study that will enroll a minimum of 41 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue imatinib. All patients must be restarted on imatinib at the time of relapse in order to be eligible for this trial.

Condition or disease Intervention/treatment Phase
Chronic Phase Chronic Myelogenous Leukemia Drug: Asciminib Drug: Imatinib Phase 2

Detailed Description:
This trial will use a combination of asciminib 40 mg by mouth (PO) twice daily (BID) plus imatinib (maximum dose of 400 mg PO once daily) in the combination treatment phase. The BCR-ABL tyrosine kinase inhibitor (TKI) that will be used for this trial is imatinib. All eligible patients will begin asciminib in combination with imatinib on cycle 1 day 1 of the combination phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). Each cycle will be ~28 days. At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment-free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their imatinib and be monitored off treatment. The primary endpoint of this study is the 12-month "second" TFR rate after completion of 12 cycles of combination therapy. Patients will remain in the TFR phase of the study for up to three years and will have central polymerase chain reaction (PCR) testing during the first two years. Therefore, the total duration of the subject participation trial will be approximately five years (one year on combination treatment phase plus three years in the TFR phase plus one year of long-term follow-up post TFR or early discontinuation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Actual Study Start Date : November 11, 2021
Estimated Primary Completion Date : June 2028
Estimated Study Completion Date : July 2029


Arm Intervention/treatment
Experimental: Combination Therapy and Remission Phase
All eligible patients will begin a combination of asciminib plus imatinib cycle 1 day 1 in the combination treatment phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will discontinue their imatinib and be monitored off treatment.
Drug: Asciminib
40 mg by mouth (PO) twice a day (BID).
Other Name: ABL001

Drug: Imatinib
400 mg by mouth (PO) once daily
Other Names:
  • Gleevec
  • Glivec




Primary Outcome Measures :
  1. One-year "second" treatment-free remission. [ Time Frame: 1 years ]
    This will be measured by the number of subjects who achieve one-year treatment-free remission after 12 months of combination therapy with imatinib plus asciminib. These subjects have previously failed a first treatment free remission attempt.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years old.
  2. Willing and able to give informed consent.
  3. Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein. Subtype classification whether b3a2 (e14a2) or b2a2 (e13a2) is not required for study eligibility.
  4. Must have a documented history of attempting only one prior imatinib discontinuation under the guidance of a treating physician.
  5. Must have met all the following criteria prior to first attempt to discontinue their imatinib:

    • Stable molecular response (MR4; < 0.01% IS) for > 2 years, as documented on at least four tests, performed at least three months apart (e.g. If a patient has had >4 PCR tests performed during the two years leading up to their initial TKI discontinuation, any value between 0.01 and 0.05% IS is considered a stable result, however, at least four tests must be < 0.01% IS).
    • Treatment with imatinib for a minimum of three years prior to discontinuing imatinib.
  6. Must have relapsed (defined as loss of major molecular response (MMR), real-time quantitative polymerase chain reaction (RQ-PCR) for BCR-ABL >0.1% IS after first attempted imatinib discontinuation.
  7. After first failed TFR attempt, must have a minimum duration of one year of retreatment with imatinib (up to 400mg PO QD), and must plan to remain on imatinib for a minimum of 12 months during the combination treatment phase.
  8. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
  9. Must have a RQ-PCR for BCR-ABL < 0.0032% IS (MR4.5) reported by the trial designated central lab at the time of study enrollment.
  10. Female patients must meet one of the following:

    • Postmenopausal for at least one year before the screening visit,
    • Surgically sterile,
    • If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through 90 days after the last dose of study drug,
    • Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
  11. Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:

    • Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose,
    • Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable,
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria:

A potential subject who meets any of the following exclusion criteria is ineligible to participate in the study.

  1. History of accelerated or blast phase CML.
  2. A second malignancy requiring active treatment.
  3. History of recent (within 12 months) acute pancreatitis or chronic pancreatitis
  4. Subjects who have previously received treatment with asciminib.
  5. Subjects with platelet (PLT) count < 100 × 109/L or an absolute neutrophil count (ANC) of < 1 × 109/L or hemoglobin < 8 g/dL.
  6. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≥3 times the institutional upper limit of normal.
  7. Creatinine ≥ 2 times the institutional upper limit of normal.
  8. Total bilirubin ≥ 1.5 times the institutional upper limit of normal (unless direct bilirubin is within normal limits).
  9. Lipase > institutional upper limit of normal.
  10. Pregnant or lactating.
  11. Unable to comply with lab appointment schedule and patient-reported outcome (PRO) assessments.
  12. Another investigational drug within four weeks of enrollment.
  13. Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol.
  14. Patient has undergone a prior allogeneic stem cell transplant.
  15. Screening 12-lead ECG showing a baseline corrected QT interval >480msec (patients with a pacemaker will still be eligible with QTc>500msec).

Eligibility for the TFR Phase:

  1. Stable molecular response (MR4.5; < 0.0032% IS) documented on at least three tests (may include TFR phase screening PCR) by the trial designated lab, performed approximately three months apart while on combination phase
  2. TFR phase screening PCR RQ-PCR for BCR-ABL < 0.0032% IS (MR4.5) by the trial designated lab
  3. ECOG 0-3
  4. Completion of 12 cycles on the combination therapy phase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04838041


Contacts
Layout table for location contacts
Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 414-805-8900 cccto@mcw.edu
Contact: Ehab Atallah, MD 414-805-4600 eatallah@mcw.edu

Locations
Layout table for location information
United States, Michigan
The Barbara Ann Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Sharon Prokop    313-576-9363    prokops@karmanos.org   
Principal Investigator: Jay Yang, MD         
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Ehab Atallah, MD    414-805-4600    eatallah@mcw.edu   
Principal Investigator: Ehab Atallah, MD         
Sponsors and Collaborators
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium
Investigators
Layout table for investigator information
Principal Investigator: Ehab Atallah, MD Medical College of Wisconsin
Study Chair: Michael J. Mauro, MD Memorial Sloan Kettering Cancer Center
Layout table for additonal information
Responsible Party: Ehab L Atallah, Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT04838041    
Other Study ID Numbers: PRO00040685
First Posted: April 8, 2021    Key Record Dates
Last Update Posted: May 5, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ehab L Atallah, Medical College of Wisconsin:
chronic myelogenous leukemia
treatment-free remission
tyrosine kinase inhibitors
H. Jean Khoury Cure CML Consortium
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action